Abstract:The aggregation of misfolded proteins, such as α-synuclein in Parkinson's disease (PD), occurs intracellularly or extracellularly in the majority of neurodegenerative diseases. The immunoproteasome has more potent chymotrypsin-like activity than normal proteasome. Thus, degradation of α-synuclein aggregation via immunoproteasome is an attractive approach for PD drug development. Herein, we aimed to determine if novel compound, 11-Hydroxy-1-(8-methoxy-5-(trifluoromethyl)quinolin-2-yl)undecan-1-one oxime (named as J24335), is a promising candidate for disease-modifying therapy to prevent the pathological progression of neurodegenerative diseases, such as PD. The effects of J24335 on inducible PC12/A53T-α-syn cell viability and cytotoxicity were evaluated by MTT assay and LDH assay, respectively. Evaluation of various proteasome activities was done by measuring the luminescence of enzymatic activity after the addition of different amounts of aminoluciferin. Immunoblotting and real-time PCR were employed to detect the expression of various proteins and genes, respectively. We also used a transgenic mouse model for behavioral testing and immunochemical analysis, to assess the neuroprotective effects of J24335. J24335 inhibited wild-type and mutant α-synuclein aggregation without affecting the growth or death of neuronal cells. The inhibition of α-synuclein aggregation by J24335 was caused by activation of immunoproteasome, as mediated by upregulation of LMP7, and increased cellular chymotrypsin-like activity in 20S proteasome. J24335-enhanced immunoproteasome activity was mediated by PKA/Akt/mTOR pathway activation. Moreover, animal studies revealed that J24335 treatment markedly mitigated both the loss of tyrosine hydroxylase-positive (TH-) neurons and impaired motor skill development. This is the first report to use J24335 as an immunoproteasome enhancing agent to antagonize pathological α-synuclein-mediated neurodegeneration.

Trehalose Inhibits Wild-Type Alpha-Synuclein Fibrillation And Overexpression And Protects Against The Protein Neurotoxicity In Transduced Pc12 Cells

Trehalose Inhibits A53T Mutant Α-Synuclein Overexpression and Neurotoxicity in Transduced PC12 Cells.

Effect of Trehalose on PC12 Cells Overexpressing Wild-Type or A53T Mutant Α-Synuclein

Trehalose Inhibits Fibrillation of A53T Mutant Alpha-Synuclein and Disaggregates Existing Fibrils

Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson’s Disease

Trehalose Alleviates PC12 Neuronal Death Mediated by Lipopolysaccharide-Stimulated BV-2 Cells via Inhibiting Nuclear Transcription Factor NF-κB and AP-1 Activation

Oral Trehalose Intake Modulates the Microbiota–Gut–Brain Axis and Is Neuroprotective in a Synucleinopathy Mouse Model

Trehalose Attenuates In Vitro Neurotoxicity of 6-Hydroxydopamine by Reducing Oxidative Stress and Activation of MAPK/AMPK Signaling Pathways

Trehalose rescues Alzheimer's disease phenotypes in APP/PS1 transgenic mice.

Profiling neuroprotective potential of trehalose in animal models of neurodegenerative diseases: a systematic review

Trehalose Rescues Alzheimer'S Disease Phenotypes in App/Ps1 Transgenic Mice

Trehalose, a Novel Mtor-Independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and Α-Synuclein

(-)-Epigallocatechin-3-gallate (EGCG) inhibits fibrillation, disaggregates amyloid fibrils of alpha-synuclein, and protects PC12 cells against alpha-synuclein-induced toxicity

Trehalose Inhibits Protein Aggregation Caused by Transient Ischemic Insults Through Preservation of Proteasome Activity, Not Via Induction of Autophagy

Analysis of a Single Α-Synuclein Fibrillation by the Interaction with a Protein Nanopore.

Inhibition effects of tanshinone on the aggregation of alpha-synuclein

2-Butoxytetrahydrofuran, Isolated from Holothuria scabra, Attenuates Aggregative and Oxidative Properties of α-Synuclein and Alleviates Its Toxicity in a Transgenic Caenorhabditis elegans Model of Parkinson's Disease

Autophagic Modulation by Trehalose Reduces Accumulation of TDP-43 in a Cell Model of Amyotrophic Lateral Sclerosis Via TFEB Activation.

Antagonizing pathological α-synuclein-mediated neurodegeneration by J24335 via the activation of immunoproteasome

Triptolide Promotes the Clearance of Α-Synuclein by Enhancing Autophagy in Neuronal Cells

Specific Knockdown of Α-Synuclein by Peptide-Directed Proteasome Degradation Rescued Its Associated Neurotoxicity